On November 18, Twist Bioscience Corp rose 4.33% in Regular Trading, trading at $116.94 per share, with turnover of $31.2725 million.
The move came as the market continued to digest the company’s latest earnings and slower AI drug discovery growth outlook, while analyst target revisions turned more mixed after several cuts were followed by a higher target from Piper Sandler.
Background context shows Twist Bioscience Corp reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus. Fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, management’s comments pointing to slower AI drug discovery-related growth continued to cap sentiment. Recent analyst actions reflect that split view: UBS cut its target to $120, Jefferies lowered its target to $125, Guggenheim reduced its target to $150, while Piper Sandler raised its target to $140 from $115.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments